

JULY 2020



News and Views



A once-weekly injection
for patients with hemophilia A

Hear about
a different
treatment option >

REGISTER
TODAY

WEBINAR

*Health Care Trends and
the Impact of COVID-19*

with **Doug Long**

Vice President of Industry Relations, IQVIA

THURSDAY, JULY 9 • 2PM ET

- FREE FOR AMCP MEMBERS
- \$69 FOR NON-AMCP MEMBERS



Doug Long to Discuss Health Care Trends and Impact of COVID-19 at AMCP Webinar, July 9 at 2pm ET

Managed care pharmacy, like the rest of health care, has adapted in the face of COVID-19. Learn how the ongoing pandemic is affecting our profession during a special June 9 AMCP webinar with **Doug Long**, vice president of industry relations at IQVIA. Long is one of the leading experts on health care and pharmaceutical marketplaces. His presentation will examine questions such as: What trends have been the most impactful so far? What is the overall effect on drug supplies? What changes implemented during the pandemic may continue even after the pandemic slows down? And is prescription demand coming back? The event is free for AMCP members and \$69 for non-AMCP members. [Learn more and register](#). For more information on the impact of COVID-19, visit [AMCP's Resource Center](#) and IQVIA's [weekly report](#).



**SEEKING APPLICATIONS
FOR AMCP'S BOARD**

Apply by September 2

Help Shape AMCP and Your Profession: Apply for Board of Directors

As a passionate member focused on ensuring patients get the medications they need at a cost they can afford, take your dedication to a new level and apply to become part of the board of directors. AMCP is seeking candidates for president-elect, treasurer, and two (2) directors. The president-elect will serve for one year in that

capacity and then one year each as president and immediate past president. The treasurer and directors serve two-year terms. AMCP active member pharmacists, physicians, nurses, or physician assistants in good standing are eligible to apply for treasurer or director. Only active member pharmacists in good standing are eligible to apply for the office of president-elect. Successful candidates will be installed at AMCP 2021 in San Francisco, April 13-16, 2021. [Apply by 5:30pm ET on Sept. 2.](#)



Perspectives From CEO Susan A. Cantrell

In her latest [blog post](#), AMCP CEO **Susan A. Cantrell**, RPh, CAE, shares a statement that she and AMCP President **Marissa Schlaifer**, MS, RPh, recently wrote and sent to members on how AMCP is taking a stand against racial injustice. Cantrell and Schlaifer describe how AMCP is working to translate broad goals into specific, long-term actions that improve patient outcomes and health equity among all Americans, including Black Americans, indigenous people, and people of color. AMCP also recently signed a [joint statement](#) with 13 other national pharmacy associations setting goals to stand against racial injustice. Your feedback and ideas are essential to AMCP as we move forward. Please email us at executiveoffice@amcp.org with your thoughts about how we can implement the actions outlined in our statement and what additional actions we need to consider as managed care pharmacy professionals. We look forward to an open dialogue as we work together toward change.



AMCP Foundation Unveils New Mission Statement, Marks 30 Year Anniversary

Coinciding with its 30th birthday, AMCP Foundation unveiled a new mission statement last month reaffirming AMCP Foundation's commitment to "strengthen managed care pharmacy by investing in future-focused research and inspiring the next generation to improve patient health." The statement was unanimously adopted by the AMCP Foundation Board of Trustees. "Our new mission statement describes the organization's purpose in a modern and aspirational tone," says **Paula J. Eichenbrenner**, MBA, CAE. "It also ties in to the AMCP mission and complements the AMCP Foundation tagline: Developing leaders. Enhancing health." Founded in June 1990, AMCP Foundation has contributed to the tools, strategies, and programs that managed care pharmacy has utilized to advance health care quality and patient



A once-weekly injection

for patients with
hemophilia A

Hear about
a different
treatment option >

outcomes. Help strengthen the mission for [30 more years with a \\$30 donation](#) (or any amount) on the AMCP Foundation website.

Congratulations to the 2020 recipient of

The Steven G. Avey Award



David Calabrese, RPh, MHP

David Calabrese, 2020 Avey Award Recipient, Shares Insights on Career and Profession

AMCP Foundation's Steven G. Avey Award represents managed care pharmacy's highest honor. Reflecting on what it means to receive the award, this year's recipient, **David Calabrese**, RPh, MHP, says, "It involves the moral obligation to closely and openly collaborate with those around us, and to make others better by openly communicating and mentoring, but at the same time, always being willing to be mentored." [Read his other observations.](#)



Join AMCP Nexus 2020 For Education, Innovation, Networking, and more, Oct. 20-23 in Las Vegas

[AMCP Nexus 2020](#) promises a wealth of educational and networking opportunities that will help you and your organization operate at peak performance. The meeting features dozens of [education sessions](#) on such hot topics as: new models to pay for innovation in the pharmaceutical pipeline; an examination of managed care foundational principles; federal and state legislation and regulation trends; new solutions that ensure patients get the medications they need at costs they can afford; and how to put the latest managed care pharmacy research into practice. The fall meeting kicks off with inspirational speaker [Sekou Andrews](#) (pictured) at the [opening general session](#). His presentation will feature rich, actionable insights that help attendees connect more deeply with their communities, become more influential leaders, and unlock greater possibilities. [Register now](#). Questions about COVID-19 and Nexus 2020? See our [COVID-19 safety information](#).



AMCP Corporate Member Spotlight: Scipher Medicine

AMCP News & Views recently caught up with **Alif Saleh**, CEO, Scipher Medicine, to learn about his company and gain insights on becoming an AMCP corporate member. Among his observations, he notes "AMCP shares our goal of getting patients the drugs and drug therapies that are appropriate for them in a safe, convenient, and cost-effective manner." [Read more.](#)



Sponsor AMCP's Partnership Forum on Rare Diseases

Does your company serve the needs of individuals suffering from rare diseases? If so, we invite your company to **sponsor AMCP's Partnership Forum, "Preparing for and Managing Rare Diseases", which will be held virtually from Sep. 8-10** (agenda 2-4 hours/day).

AMCP Partnership Forums convene decision makers in managed and integrated care and life science companies to discuss key issues facing managed care pharmacy and collaboratively help shape the changing health care landscape.

The forum on rare diseases will focus on the role of managed care organizations, life science companies, prescribers, patients, employers, and the government in supporting access to million-dollar, breakthrough therapies as well as identifying and managing these small but important patient populations in a changing health care system post COVID-19.

Forums are invitation-only and are supported by sponsorship. Forum findings are shared with managed care professionals via webinars and proceedings published in the *Journal of Managed Care & Specialty Pharmacy*. Sponsors can also work with AMCP to share forum findings with the FDA and policymakers.

Join the conversation to identify key actions that can support timely access to and the appropriate management of treatments for rare diseases. **Email corpopportunities@amcp.org to become a corporate sponsor.**



Regulatory Update

CMS Issues Proposed Rule Updating the Medicaid Drug Rebate Program; Member Feedback Sought to Shape AMCP Comments: CMS recently issued a [proposed rule](#) updating the Medicaid Drug Rebate Program (MDRP) to better account for value-based purchasing (VBP) programs between manufacturers and states and other payers. The proposed rule details how manufacturers should account for VBP programs in their reporting of the manufacturer "best price," for the purposes of determining rebate amounts in the Medicaid program. In the

proposed rule, CMS more specifically defines what a VBP program is and modifies the MDRP regulations to allow for a single drug to have multiple price points due to a VBP program. This is a major departure from CMS's historical interpretation of the calculation of best price, which was based on a single price. Additionally, the proposed rule clarifies how the use of copay accumulator programs should be accounted for in the reporting of best price. [Read AMCP's summary](#). Comments must be submitted to CMS by July 20. Provide feedback to advocacy@amcp.org by July 13.

CMS Delays Implementation of Electronic Prior Authorization Requirements: CMS recently issued a guidance delaying implementation of a proposal that would have required all Part D plans to utilize technology supporting the National Council of Prescription Drug Plans (NCPDP) SCRIPT standard for electronic prior authorizations by Jan. 1, 2021. CMS proposed this requirement in a 2019 rule but is delaying its finalization due to the ongoing COVID-19 public health emergency. CMS aims to minimize the burden on plan sponsors and ensure that the agency has the resources to continue to address the public health emergency. Read AMCP's [comments](#) on the 2019 proposed rule.



July Webinars: A Wealth of Continuing Education Opportunities

AMCP is proud to present a growing number of webinars covering a wide range of managed care pharmacy topics. All are free to members and start at 2pm ET. Mark your calendars for the following:

- July 8: [COPD: Simplifying a Complex Treatment Paradigm for Managed Care](#)
- July 9: [Health Care Trends and the Impact of COVID-19](#)
- July 15: [Navigating Changes in Clostridioides difficile Prevention and Treatment](#)
- July 16: (PIE Webinar) [Taiho Oncology Inc. has an investigational product being evaluated for the treatment of Myelodysplastic Syndromes \(MDS\)](#)
- July 23: [Switching from Reference Medicines to Biosimilars](#)
- July 28: [What's Next for Specialty Medication Benefit Design and Reimbursement - Proceedings from the AMCP Partnership Forum](#)
- July 29: (PIE Webinar): [The Patient Journey: Barriers to Identifying, Diagnosing, and Initiating Treatment for Alzheimer's Disease Patients](#)
- July 30: [Latest Developments in Migraine Treatment: Key Considerations for Decision-Makers](#)
- Aug. 4: [Understanding Dementia-Related Psychosis: Dementia-Related Hallucinations and Delusions Are Associated With Significant Unmet Medical Need](#)

If you've attended AMCP webinars in the past we'd love to hear from you! [Share your experience with this quick poll](#).



PIE Webinar: Taiho Oncology Inc. has an investigational product being evaluated for the treatment of Myelodysplastic Syndromes (MDS)

AMCP will host a [pre-approval information exchange \(PIE\) webinar](#) sponsored, developed and presented by Taiho Oncology Inc. July 16 at 2pm ET. The FDA has accepted an NDA for oral C-DEC (cedazuridine and decitabine) as a treatment for myelodysplastic syndromes (MDS). Myelodysplastic syndromes (MDS) are a rare group of bone marrow failure disorders, where the body no longer makes enough healthy, normal blood cells in the bone marrow. Treatment for MDS is a lifelong condition without transplant. C-DEC is a fixed-dose combination of decitabine, a hypomethylating agent (HMA), and cedazuridine, a cytidine deaminase. This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. To register for this webinar, log into FormularyDecisions and click on the “Register” link found on the home page in the Webinars section. In order to join the webinar, please register as a payer. [Register here](#).



PIE Webinar: The Patient Journey: Barriers to Identifying, Diagnosing, and Initiating Treatment for Alzheimer’s Disease Patients

AMCP will host a [pre-approval information exchange \(PIE\) webinar](#) sponsored, developed and presented by Biogen on Wednesday, July 29, from 2-3pm ET. The US healthcare system faces a significant challenge due to the growth in the prevalence rate of Alzheimer’s disease and the costs due to its management. An initial step to addressing this challenge may be to identify patients in the early stages of AD and confirm diagnosis so that they may benefit if future treatments become available. This session will explore how appropriate patients may be identified, as well as the potential barriers to diagnosis and treatment initiation faced by patients, care persons, providers, and the surrounding service ecosystem. This webinar is only offered to payers, formulary committees, or other similar entities responsible for the selection of drugs for coverage or reimbursement. [Register here](#).



**Preapproval
Information
Exchange**

FormularyDecisions™
AmerisourceBergen

Access Information Earlier: PIE Webinars Now Available on FormularyDecisions

For a great preapproval information exchange (PIE) source, turn to AMCP PIE webinars. Available exclusively on FormularyDecisions, these webinars allow life sciences organizations to provide payers and other health care decision makers helpful information early in the process to enhance formulary planning and budget forecasting. For a full schedule of available webinars, login to [FormularyDecisions](#). Payers who are not current users can register for free at [FormularyDecisions.com](#) or manufacturers can contact information@formularydecisions.com for subscription options.

AMCP

675 North Washington Street, Suite 220, Alexandria, VA 22314
703 684 2600 | www.amcp.org

Editor Neal Learner, Press Officer & Content Editor

For inquiries or submissions, please contact nlearner@amcp.org.